Research Associate, Next Generation Sequencing

Our mission is to make biology easier to engineer. Ginkgo is constructing, editing, and redesigning the living world in order to answer the globe’s growing challenges in health, energy, food, materials, and more. Our bioengineers make use of an in-house automated foundry for designing and building new organisms.

Ginkgo's NGS group enables diverse synthetic biology projects by providing sequencing services to organism engineering teams. Our services include DNA and RNA sequencing using short read (Illumina) and long read (PacBio and Oxford Nanopore) platforms. We confirm synthetic constructs, genomic edits, and expression profiles of engineered organisms. We help develop the next generation of therapeutics in RNA and gene therapy.

As a Research Associate in our NGS group, you will empower Ginkgo’s organism engineers with high-quality and high-throughput RNA extraction, RNA sequencing, and qPCR services. By adding your own expertise to an interdisciplinary team of bench scientists, computational biologists, data scientists, and software engineers, your role will be critical to developing world-changing methods for engineering biology.

To learn more about Ginkgo, visit www.ginkgobioworks.com/press/ or check out some curated press below:

What is it really like to take your company public via a SPAC? One Boston biotech shares its journey (Fortune)

Ginkgo Bioworks resizes the definition of going big in biotech, raising $2.5B in a record SPAC deal that weighs in with a whopping $15B-plus valuation (Endpoints News)

Ginkgo Bioworks CEO on scaling up Covid-19 testing: ‘If we try, we can win’ (CNBC)

Ginkgo raises $70 million to ramp up COVID-19 testing for employers, universities (Boston Globe)

Ginkgo Bioworks Redirects Its Biotech Platform to Coronavirus (Wall Street Journal)

Ginkgo Bioworks Provides Support on Process Optimization to Moderna for COVID-19 Response (PRNewswire)

The Life Factory: Synthetic Organisms From This $1.4 Billion Startup Will Revolutionize Manufacturing (Forbes)

Synthetic Bio Pioneer Ginkgo Raises $290 Million in New Funding (Bloomberg)

Ginkgo Bioworks raises $350 million fund for biotech spinouts (Reuters)

Can This Company Convince You to Love GMOs? (The Atlantic)

We also feel that it’s important to point out the obvious here – there’s a serious lack of diversity in our industry, and that needs to change. Our goal is to help drive that change. Ginkgo is deeply committed to diversity, equity, and inclusion in all of its practices, especially when it comes to growing our team. Our culture promotes inclusion and embraces how rewarding it is to work with people from all walks of life.

We’re developing a powerful biological engineering platform, so we must remain mindful of the many ways our technology can – and will – impact people around the world. We care about how our platform is used, and having a diverse team to build it gives us the best chance that it’s something we’ll be proud of as it continues to grow. Therefore, it’s critical that we incorporate the diverse voices and visions of all those who play a role in the future of biology.

It is the policy of Ginkgo Bioworks to provide equal employment opportunities to all employees and employment applicants.